We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis.
Up to 70% of all breast, ovarian, and endometrial cancers express the progesterone receptor (PR) and are thus said to be PR+.
The progesterone receptor belongs to the steroid receptor family, a subset of the nuclear receptor family, and is the mediator of progesterone action. PR is an oncogenic transcription factor that is activated by progesterone and that plays a key role in hormonally-regulated tissues such as breast. The PR is expressed in normal cells and in certain malignant tissues, mediating the effects of progesterone by association with a range of co-regulatory proteins and binding to specific target sequences in progesterone-regulated gene promoters.
If your cancer is PR+, Apristor could be an option for you.